



OIST

OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY GRADUATE UNIVERSITY  
沖縄科学技術大学院大学

# Novel macrolactam compound produced by the heterologous expression of a large cryptic biosynthetic gene cluster of *Streptomyces rochei* IF012908

Author	Takuya Hashimoto, Ikuko Kozone, Junko Hashimoto, Reiko Ueoka, Noritaka Kagaya, Manabu Fujie, Noriyuki Sato, Haruo Ikeda, Kazuo Shin-ya
journal or publication title	The Journal of Antibiotics
volume	73
number	3
page range	171-174
year	2019-12-18
Publisher	Nature Research
Rights	(C) 2019 The Author(s), under exclusive licence to the Japan Antibiotics Research Association
Author's flag	author
URL	<a href="http://id.nii.ac.jp/1394/00001386/">http://id.nii.ac.jp/1394/00001386/</a>

doi: info:doi/10.1038/s41429-019-0265-x

1 Novel macrolactam compound produced by heterologous expression of a  
2 large cryptic biosynthetic gene cluster of *Streptomyces rochei* IFO12908

3 *Takuya Hashimoto,<sup>1</sup> Ikuko Kozono,<sup>2</sup> Junko Hashimoto,<sup>2</sup> Reiko Ueoka,<sup>1</sup> Noritaka Kagaya,<sup>1</sup> Manabu*  
4 *Fujie,<sup>3</sup> Noriyuki Sato,<sup>3</sup> Haruo Ikeda,<sup>4</sup> and Kazuo Shin-ya<sup>\*,1,5,6</sup>*

5 <sup>1</sup> National Institute of Advanced Industrial Science and Technology, 2-4-7 Aomi, Koto-ku, Tokyo,  
6 135-0064, Japan.

7 <sup>2</sup> Japan Biological Informatics Consortium (JBIC), 2-4-7 Aomi, Koto-ku, Tokyo, 135-0064, Japan.

8 <sup>3</sup> Okinawa Institute of Science and Technology Graduate University, 1919-1 Tancha, Onna-son,  
9 Kunigami-gun, Okinawa 904-0495, Japan.

10 <sup>4</sup> Kitasato Institute for Life Sciences, Kitasato University, 1-15-1 Kitasato, Minami-ku, Sagami-hara,  
11 Kanagawa 252-0373, Japan

12 <sup>5</sup> Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, 1-1-1  
13 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.

14 <sup>6</sup> Biotechnology Research Center, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-  
15 8657, Japan.

1 **Keywords:** cytotoxic/heterologous expression/macrolactam /

2

1 **Abstract.**

2 In the course of our studies on the heterologous expression of giant biosynthetic genes, we discovered  
3 a novel cryptic biosynthetic gene cluster in *Streptomyces rochei* IFO12908. During our efforts to  
4 express biosynthetic genes using the host SUKA strain derived from *Streptomyces avermitilis*, a novel  
5 polyene macrolactam compound designated as JBIR-156 was produced. We report herein the  
6 cloning and heterologous expression of the JBIR-156 biosynthetic gene cluster, and the isolation,  
7 structure determination, and cytotoxic activity of this novel compound.

8

1 Screening for bioactive microbial secondary metabolites has been performed for more than 70  
2 years. The search for bioactive natural metabolites has resulted in great benefits to humankind,  
3 although the rate of discovery of skeletally-novel compounds from bacteria has significantly  
4 decreased over time. (ref. 1, 2) New technologies to discover novel natural compounds are strongly  
5 desired. To overcome this problem, new techniques to express cryptic biosynthetic gene clusters  
6 for secondary metabolites are needed to access novel compounds. Furthermore, aside from the  
7 classical techniques including improvement of cultural conditions for wild-type strains, heterologous  
8 expression technology is considered to be one of the most promising strategies since the resultant  
9 production of microbial secondary metabolites can be performed under a common platform.

10 On the other hand, *Streptomyces* is known as a representative microorganism to produce potent  
11 natural products. (ref. 3) Recent advances in genome sequencing projects have revealed that a large  
12 number of biosynthetic gene clusters are encoded in the genome of *Streptomyces*. For the expression  
13 of biosynthetic gene clusters, genetically engineered *Streptomyces* strains such as *Streptomyces*  
14 *coelicolor* M1152, M1154, and *Streptomyces avermitilis* derived SUKA strains, have been developed.  
15 (ref. 4-6) In these engineered strains, endogenous metabolic pathways were removed to avoid  
16 competition of substrate usages between endogenous and exogenously introduced secondary  
17 metabolites. (ref. 7) In addition, this engineered host can afford a clean metabolic background,  
18 which makes it easier to isolate relevant compounds.

19 Despite the many heterologous expression experiments for the production of microbial secondary  
20 metabolites performed over the past two decades, (ref. 8) only a few examples of the heterologous  
21 expression of biosynthetic gene clusters over 100 kb in size have been reported (ref. 9) because it is  
22 extremely difficult to clone and introduce such giant biosynthetic gene clusters into the host strain.  
23 During the course of our focused efforts to establish a technique for the heterologous expression of  
24 large size biosynthetic gene clusters, we developed our technology for cloning larger biosynthetic  
25 gene clusters employing BAC vectors (up to 300 kb genome libraries can be prepared with BAC  
26 vectors). As a result of our studies, we succeeded in the heterologous production of mediomycin,

1 neomediomycin, (ref. 10) and quinolidomicin. (ref. 11) To express cryptic and/or unreported gene  
2 clusters with our system, we searched biosynthetic gene clusters larger than 100 kb from our in-house  
3 genome sequence data bank consisting of more than 100 actinomycete strains. Among such large  
4 biosynthetic gene clusters, we selected a gene cluster including type-I PKSs with glutamate mutase  
5 genes, which could produce a macrolactam compound in the genome of *Streptomyces rochei*  
6 IFO12908. As well known that macrolactam compounds can exhibit potent cytotoxic activities.  
7 On the other hand, macrolactam compounds are extremely difficult to obtain because of highly  
8 vulnerable character. It was expected that such unstable compounds showing strong bioactivities  
9 can be obtained by applying our heterologous expression techniques. Heterologous expression of  
10 the BAC clone containing a whole biosynthetic gene cluster of the type-I PKS resulted in the  
11 production of a novel polyene macrolactam compound designated as JBIR-156 (**1**). Here we report  
12 the cloning, heterologous expression of the gene cluster, isolation, structure determination, and brief  
13 biological activities of **1**.

14 We scanned the draft genome sequence of *S. rochei* IFO12908 strain and found a biosynthetic  
15 gene cluster over 100 kb which encodes 5 polyketide synthases (PKSs). Among the PKS modules  
16 of JBIR-156 (**1**), a total of 9 of the 10 modules include the dehydratase (DH) and ketoreductase (KR)  
17 domains, which compose the double bonds at  $\beta$ -keto groups of acyl-carrier protein (ACP)-bound  
18 intermediates. Therefore, this biosynthetic product is expected to consist of highly conjugated  
19 double bonds. The putative biosynthetic gene cluster including adjacent genes responsible for the  
20 production of the compound was estimated at 140 kb at most. For cloning of the gene cluster, a  
21 BAC DNA library of the *S. rochei* IFO12908 strain was prepared as previously described. (ref. 12,  
22 13) A clone, pKU518F6K295\_P1\_P9-M23 (insert size: 234 kb), containing the biosynthetic gene  
23 cluster was picked up by PCR screening which amplified the upstream and downstream of the target  
24 gene cluster from the constructed DNA library. The pKU518F6K295\_P1\_P9-M23 was introduced  
25 into the SUKA32 strain to obtain a transformant, SUKA32::pKU518F6K295\_P1\_P9-M23. The  
26 obtained clone was cultivated in 50-mL test tubes, each containing 15 mL of a seed medium consisting

1 of 0.5% glucose, 1.5% Soya Flour and 0.5% yeast extract. The test tubes were shaken on a  
2 reciprocal shaker (320 r.p.m.) at 27 °C for 2 days. Aliquots (2.5 mL) of the culture were transferred  
3 into 500-mL baffled Erlenmeyer flasks filled with 100 mL of a production medium consisting of 2%  
4 glycerol, 1% molasses, 0.5% casein, 0.1% polypepton and 0.4% CaCO<sub>2</sub> (adjusted pH to 7.2 before  
5 sterilization), and cultured on a rotary shaker (180 r.p.m.) at 27 °C for 5 days.

6 We executed comparative analyses of the transformant and null strains of SUKA32. According  
7 to the structural prediction of the biosynthetic gene cluster of JBIR-156, **1** could show characteristic  
8 polyene UV absorption. A specific peak showing polyene UV absorption was appeared in the  
9 extract of the mycelial cake of transformant. The fermentation broth (1 L) was centrifuged to collect  
10 a mycelial cake, which was extracted with 200 mL of acetone three times. Acetone was evaporated  
11 *in vacuo*, and the residual aqueous layer was extracted with ethyl acetate twice. The resultant ethyl  
12 acetate layer was concentrated to dryness (321 mg). The sample was subjected to ODS RP-MPLC  
13 (Purif-Pack ODS-60 Shoko Scientific Co., Yokohama, Japan) by using a H<sub>2</sub>O–MeOH stepwise  
14 solvent system (0%, 40%, 60%, 80%, and 100% MeOH). The 80% MeOH fraction was collected  
15 and lyophilized (30.7 mg). The fraction was further purified by RP HPLC employing a Develosil  
16 RPAQUEOUS-AR5 C<sub>30</sub> column (20 i.d. × 150 mm, Nomura Chemical, Seto, Japan), in isocratic  
17 mode with 55% CH<sub>3</sub>CN (flow rate 10 ml min<sup>-1</sup>) to afford a pure sample of **1** (3.6 mg).

18 Compound **1** was obtained as a brownish powder.  $[\alpha]_D^{24} -25$  (*c* 0.02, MeOH); UV (MeOH)  
19  $\lambda_{\max}$  (log  $\epsilon$ ) 264 nm (4.22), 303 nm (4.53), 313 nm (4.54), 348 nm (4.11); IR (ATR)  $\nu_{\max}$  3400 and  
20 1646 cm<sup>-1</sup>. The UV spectrum of **1** suggested that **1** consisted of a polyene structure. Its molecular  
21 formula was established as C<sub>24</sub>H<sub>29</sub>NO<sub>2</sub> by HR-ESIMS ( $[M+H]^+$ , *m/z* 364.2270, calcd for C<sub>24</sub>H<sub>30</sub>NO<sub>2</sub>,  
22 364.2271). The structure determination of **1** was performed based on <sup>1</sup>H, <sup>13</sup>C NMR and a series of  
23 2D NMR analyses, double quantum filtered COSY (DQF-COSY), gradient-enhanced heteronuclear  
24 single quantum coherence with adiabatic pulses (HSQCAD), and gradient-selected heteronuclear  
25 multiple bond correlation using adiabatic pulses (HMBCAD). The <sup>13</sup>C and <sup>1</sup>H NMR data for **1** are  
26 listed in Table 1. The well-resolved DQF-COSY spectrum of **1** indicated two partial structures.

1 The sequence from a doublet olefinic methine proton 2-H ( $\delta_{\text{H}}$  5.64) to an olefinic methine proton 18-  
2 H ( $\delta_{\text{H}}$  6.15) through olefinic methine protons 3-H ( $\delta_{\text{H}}$  6.33), 4-H ( $\delta_{\text{H}}$  7.35), 5-H ( $\delta_{\text{H}}$  6.87), 6-H ( $\delta_{\text{H}}$   
3 6.33), 7-H ( $\delta_{\text{H}}$  6.55), 8-H ( $\delta_{\text{H}}$  6.62), 9-H ( $\delta_{\text{H}}$  5.69), aliphatic methylene protons 10-H<sub>2</sub> ( $\delta_{\text{H}}$  2.27, 2.95),  
4 an oxymethine proton 11-H ( $\delta_{\text{H}}$  4.47,  $\delta_{\text{C}}$  68.7), olefinic methine protons 12-H ( $\delta_{\text{H}}$  5.60), 13-H ( $\delta_{\text{H}}$   
5 5.90), 14-H ( $\delta_{\text{H}}$  6.13), 15-H ( $\delta_{\text{H}}$  6.38), 16-H ( $\delta_{\text{H}}$  5.97), and 17-H ( $\delta_{\text{H}}$  6.36) was observed. Another  
6 <sup>1</sup>H sequence was established by the <sup>1</sup>H spin system from an olefinic methine proton 19-H ( $\delta_{\text{H}}$  6.17)  
7 to an amide proton NH ( $\delta_{\text{H}}$  7.98) *via* olefinic methine protons 20-H ( $\delta_{\text{H}}$  6.50), 21-H ( $\delta_{\text{H}}$  5.19), a  
8 methine proton 22-H ( $\delta_{\text{H}}$  3.40) which in turn coupled to methyl protons 24-H<sub>3</sub> ( $\delta_{\text{H}}$  0.92) and nitrogen  
9 atom connected methylene protons 23-H<sub>2</sub> ( $\delta_{\text{H}}$  2.35, 3.39,  $\delta_{\text{C}}$  45.9). Although, the <sup>3</sup>J<sub>H,H</sub> value  
10 between 18-H and 19-H (11.3 Hz) was read from a coupled HSQC spectrum, the linkage between C-  
11 18 and C-19 was confirmed by the HMBC correlation as described *vide infra*.

12 The connectivity between these two moieties was established as follows. In the HMBC  
13 spectrum, <sup>1</sup>H-<sup>13</sup>C long-range couplings from the olefinic methine proton 17-H ( $\delta_{\text{H}}$  6.36) to an olefinic  
14 methine carbon C-19 ( $\delta_{\text{C}}$  125.9), and from an olefinic proton 20-H ( $\delta_{\text{H}}$  6.50) to an olefinic methine  
15 carbon C-18 ( $\delta_{\text{C}}$  123.3), established the connection between C-18 and C-19. A macrolactam  
16 structure was established by the <sup>1</sup>H-<sup>13</sup>C long-range couplings from the olefinic protons 2-H, 3-H, 23-  
17 H<sub>2</sub> and the amide proton 23-NH to an amide carbonyl carbon C-1 ( $\delta_{\text{C}}$  166.9). Based on the index of  
18 hydrogen deficiency of **1** together with the proton and carbon chemical shifts, it was determined that  
19 a hydroxy group was deduced to be substituted at the position of C-11. The geometrical  
20 configurations at C-2, C-4, C-6, C-8, C-12, C-14, C-16, C-18 and C-20 were established as *Z*, *E*, *Z*,  
21 *Z*, *E*, *E*, *Z*, *Z* and *Z*, respectively, according to the <sup>3</sup>J<sub>H,H</sub> values, ( $J_{2,3} = J_{6,7} = J_{8,9} = J_{16,17} = J_{18,19} = J_{20,21}$   
22 = 10 - 12 Hz and  $J_{4,5} = J_{12,13} = J_{14,15} = 14 - 16$  Hz). Thus, the gross structure including the geometry  
23 of **1** was established as shown in Figure 1.

24 We annotated the functions of the genes in the biosynthetic gene cluster as shown in Table S1  
25 and a plausible biosynthetic pathway is illustrated in Figure S2. The biosynthetic gene cluster for  
26 JBIR-156 resembles those of polyene macrolactams such as vicenistatin, (ref. 14) ML-449 (ref. 15)

1 and sceliphrolactam. (ref. 16) The biosynthesis of the starter unit in the PKS of **1** occurs through the  
2 same pathway as that of vicienistatin. Biosynthesis is initiated from the conversion of L-glutamic  
3 acid to (2*S*,3*S*)-3-MeAsp by ORF H and I. Following this reaction, ORF K, J and E form an  
4 intermediate on a carrier protein ORF L, which is then loaded onto PKS by ORF F (Figure S2). (ref.  
5 17) Consequently, the absolute configuration at the position of C-22 of **1** is predicted to be *S* as  
6 shown in Figure S2, because the methyl residue at C-22 is derived from (2*S*,3*S*)-3-MeAsp. The  
7 biosynthetic intermediates on the PKS for the formation of the macrolactam, which is predicted from  
8 the information of its domain organization, are shown in Figure S2. The intermediates on PKS  
9 deduced from the domain architecture coincide well with the structure of JBIR-156. The formation  
10 of absolute configurations of chiral carbons substituted by hydroxy residues in type-I PKS can be  
11 regulated by the sequence of KR domains. The KR domain on Module 6 that introduces the hydroxy  
12 residue at C-11 is of the A-type, forming an L-configuration of the ACP-bound intermediates. The  
13 other KR domains that reside with DH domains in the other modules are all B-type. Therefore, the  
14 putative absolute configurations at C-11 and C-22, which are substituted by the hydroxy and the  
15 methyl groups, respectively, are shown in Figure S2.

16 Since potent cytotoxic activities are often induced by polyene macrolactam compounds, we  
17 examined the cytotoxic activities of **1** against human ovarian adenocarcinoma SKOV-3, malignant  
18 pleural mesothelioma Meso-1 and T lymphoma Jurkat cells. As the result of cytotoxic test, **1**  
19 exhibited cytotoxicities against SKOV-3 and Jurkat cells with the IC<sub>50</sub> values of 9.45 and 3.51 μM,  
20 respectively. **1** also showed weak cytotoxicity against Meso-1 (IC<sub>50</sub> value: > 10 μM). The  
21 cytotoxic activities of **1** were almost the same magnitudes as those of etoposide (IC<sub>50</sub> values of  
22 etoposide against SKOV-3, Meso-1 and Jurkat cells were 2.4 μM, 39.3 μM and 0.5 μM, respectively),  
23 while camptothecin showed more potent activities against SKOV-3, Meso-1 and Jurkat cells with  
24 IC<sub>50</sub> values of 33 nM, 7,100 nM and 4.3 nM, respectively.

25 Compound **1** structurally resembles cyclamenol A (ref. 18), vicienistatin and NOVO4 (ref. 19)  
26 aglycons. Compound **1** was first isolated as the result of heterologous expression of the cryptic

1 biosynthetic gene cluster in SUKA host strain, from which endogenous biosynthetic gene clusters  
2 were knocked out. Since **1** consists of polyene moieties well known to be vulnerable to oxygen, **1**  
3 is degraded through the isolation process in which compounds are exposed to oxygen. The cultural  
4 metabolite of wild-type producing strain *S. rochei* IFO12908 contains many impurities, therefore it  
5 requires more isolation steps to obtain pure sample of **1**. Moreover, the production yield of **1** by  
6 wild type strain is about 4-fold less than that of the SUKA22 transformant. Comparatively the clean  
7 metabolic background and the higher production yield of heterologous expression in SUKA32 strain  
8 make it easier the isolation process. Thus, our heterologous expression system could be a promising  
9 technology for the production of even unstable compounds. Further studies on the heterologous  
10 expression of various cryptic biosynthetic genes are now underway.

11

1

2 **■ AUTHOR INFORMATION**

3 **Corresponding Author**

4 \*Phone/fax: +81-3-3599-8305. E-mail: k-shinya@aist.go.jp (K. Shin-ya).

5 **ORCID**

6 Kazuo Shin-ya: 0000-0002-4702-0661

7 Takuya Hashimoto: 0000-0002-6261-453X

8 **Notes**

9 The authors declare no competing financial interest.

10

11 **■ ACKNOWLEDGEMENTS**

12 This work was supported by Japan Agency for Medical Research and Development (AMED)

13 under Grant Number JP17ae0101002 for KS.

14

15

1 ■ REFERENCES

2

- 3 1. Palazzolo AME, Simons CLW, Burke MD, The natural productome. Proc. Natl. Acad. Sci. U.  
4 S. A. 2017;114:5564-6.
- 5 2. Pye CR, Bertin MJ, Lokey RS, Gerwick WH, Linington RG, Retrospective analysis of natural  
6 products provides insights for future discovery trends. Proc Natl Acad Sci U S A.  
7 2017;114:5601-6.
- 8 3. Doroghazi JR, et al. A roadmap for natural product discovery based on large-scale genomics and  
9 metabolomics. Nat Chem Biol. 2014;10:963-8.
- 10 4. Gomez-Escribano JP, Bibb MJ, Engineering *Streptomyces coelicolor* for heterologous  
11 expression of secondary metabolite gene clusters. Microb Biotechnol. 2011;4:207-15.
- 12 5. Komatsu M, Uchiyama T, Omura S, Cane DE, Ikeda H. Genome-minimized *Streptomyces* host  
13 for the heterologous expression of secondary metabolism. Proc Natl Acad Sci U S A.  
14 2010;107:2646-51.
- 15 6. Izumikawa M, et al. Novel thioviridamide derivative--JBIR-140: heterologous expression of the  
16 gene cluster for thioviridamide biosynthesis. J Antibiot. 2015;68:533-6.
- 17 7. Ikeda H, Shin-ya K, Omura S, Genome mining of the *Streptomyces avermitilis* genome and  
18 development of genome-minimized hosts for heterologous expression of biosynthetic gene  
19 clusters. J Ind Microbiol Biotechnol. 2014;41:233-50.
- 20 8. Nah HJ, Pyeon HR, Kang SH, Choi SS, Kim ES. Cloning and heterologous expression of a large-  
21 sized natural product biosynthetic gene cluster in *Streptomyces* species. Front Microbiol.  
22 2017;8:394.
- 23 9. Hashimoto T, et al. Biosynthesis of versipelostatin: identification of an enzyme-catalyzed [4+2]-  
24 cycloaddition required for macrocyclization of spirotetronate-containing polyketides. J Am

- 1 Chem Soc. 2015;137:572-5.
- 2 10. Zhang L, et al. Characterization of giant modular PKSs provides insight into genetic mechanism  
3 for structural diversification of aminopolyol polyketides. *Angew Chem Int Ed.* 2017;56:1740-5.
- 4 11. Hashimoto T, et al. Biosynthesis of quinolidomicin, the largest known macrolide of terrestrial  
5 origin: identification and heterologous expression of a biosynthetic gene cluster over 200 kb.  
6 *Org Lett.* 2018;20:7996-9.
- 7 12. Komatsu M, et al. Engineered *Streptomyces avermitilis* host for heterologous expression of  
8 biosynthetic gene cluster for secondary metabolites. *ACS Synth Biol.* 2013;2:384-96.
- 9 13. Kim JH, Komatsu M, Shin-ya K, Omura S, Ikeda H. Distribution and functional analysis of the  
10 phosphopantetheinyl transferase superfamily in *Actinomycetales* microorganisms. *Proc Natl*  
11 *Acad Sci U S A.* 2018;115:6828-33.
- 12 14. Ogasawara Y, et al. Cloning, sequencing, and functional analysis of the biosynthetic gene cluster  
13 of macrolactam antibiotic vicenistatin in *Streptomyces halstedii*. *Chem Biol.* 2004;11:79-86.
- 14 15. Jorgensen H, Degnes KF, Dikiy A, Fjaervik E, Klinkenberg G, Zotchev SB. Insights into the  
15 evolution of macrolactam biosynthesis through cloning and comparative analysis of the  
16 biosynthetic gene cluster for a novel macrocyclic lactam, ML-449. *Appl Environ Microbiol.*  
17 2010;76:283-93.
- 18 16. Low ZJ, Pang LM, Ding Y, Cheang QW, Hoang KLM, Tran HT, Li J, Liu XW, Kanagasundaram  
19 Y, Yang L, Liang ZX. Identification of a biosynthetic gene cluster for the polyene macrolactam  
20 sceliphrolactam in a *Streptomyces* strain isolated from mangrove sediment. *Sci Rep.*  
21 2018;8:1594.
- 22 17. Kudo F, Miyanaga A, Eguchi T. *Nat Prod Rep* 2014;31:1056-73.
- 23 18. Müller H, et al. German Patent DE 4231289. 1994.
- 24 19. Peoples A, Zhang Q, Moore C, Lewis K, et al. US2009/0149395. 2009.
- 25
- 26